Sterilized Multipotent Cell Compositions for Tissue Repair

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic methods for tissue repair, such as using stem cells, face challenges including immune rejection, inconvenience, and the risk of viral transmission, particularly with allogeneic cell use, which limits their effectiveness and safety in treating tissue injuries like tendon and ligament damage.

Innovation Solution

Development of novel compositions comprising sterilized and virus-inactivated multipotent cells or microvascular tissue, which are not cultured and can be stored for extended periods, offering angiogenic and anti-inflammatory activity, allowing for allogeneic or xenogeneic use without immune response and viral contamination risks.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If allogeneic stem cells are used for tissue repair, then treatment effectiveness is improved, but immune rejection and viral transmission risks increase

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidimmune rejection and viral transmission

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and removes harmful components (viruses, immunogenic elements) from the allogeneic stem cell composition through sterilization and processing, while retaining the therapeutic beneficial components that promote tissue repair and regeneration

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent applies sterilization and virus inactivation treatments that would normally destroy cellular function, but instead converts these potentially harmful processes into beneficial outcomes by eliminating pathogens while preserving the therapeutic angiogenic and anti-inflammatory properties of the composition

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Object-affected harmful factors

If autologous stem cells are used for tissue repair, then immune rejection and viral transmission risks are reduced, but treatment convenience and time efficiency worsen

Engineering Contradiction:

Improveimmune rejection and viral transmissionVSAvoidtreatment time and procedural complexity

Core Design Contradiction:

Object-affected harmful factorsVSLoss of time

Solution Approach 1:

The patent prepares allogeneic stem cell compositions in advance with sterilization and virus inactivation treatments, creating pre-tested, ready-to-use therapeutic products that eliminate the need for time-consuming autologous cell collection, processing, and quality control procedures at the time of treatment

Inventive Principle:

Principle #10Preliminary action

3Quantity of substance

If stem cells are cultured for therapy, then cell quantity and quality are improved, but treatment time and complexity increase

Engineering Contradiction:

Improvecell quantity and qualityVSAvoidprocessing time

Core Design Contradiction:

Quantity of substanceVSLoss of time

Solution Approach 1:

The patent performs cell expansion and quality optimization in advance during the manufacturing phase, creating concentrated, high-quality stem cell compositions that are ready for immediate clinical use without requiring time-consuming culture expansion procedures at the treatment site

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS10617792B2Compositions and methods for treating and preventing tissue injury and disease

Publication Date: 2020.04.14 MICROVASCULAR TISSUES INC

AI summary

The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.